



Sarcoma and GIST Conference

Programme Book

Milan, Italy

18-19 February 2014

CONFERENCE PROGRAMME

Tuesday, 18 February 2014

- 10:00/ **Welcome**
- 10:45 *Chairs: Jean-Yves Blay, Lyon, France, Paolo G. Casali, Milan, Italy and A. Paolo Dei Tos, Treviso, Italy*
- 10:00 Welcome on behalf of ESMO
Paolo G. Casali, Milan, Italy
- 10:05 Welcome on behalf of INT: The scope of personalised oncology
Marco A. Pierotti, Milan, Italy
- 10:15 The need for clinical networking in sarcomas
Jean-Yves Blay, Lyon, France
- 10:20 Welcome from patients
Roger Wilson, London, UK
- 10:30 Conference presentation
A. Paolo Dei Tos, Treviso, Italy
- 10:35 Welcome from the other side of the Atlantic
Jonathan A. Fletcher, Boston, MD, US
Lee Helman, Bethesda, MD, US
-
- 10:45/ **GIST – “sensitive”**
- 12:30 *Chairs: Toshiro Nishida, Kashiwa, Chiba, Japan and Maria A. Pantaleo, Bologna, Italy*
- 10:45 The spectrum of KIT- and PGFRA-mutated GIST
Maria Debiec-Rychter, Leuven, Belgium
- 11:00 Towards a classification of wild-type GIST
Eva Wardelmann, Muenster, Germany
- 11:15 Personalising the scalpel
Ronald P. DeMatteo, New York, NY, US
- 11:30 Personalising the adjuvant choice
Heikki Joensuu, Hyks, Finland
- 11:45 Personalising medical therapy on genotype
Jonathan C. Trent, Miami, FL, US
- 12:00 Personalising medical therapy on the rest
Michael Montemurro, Zurich, Switzerland
- 12:15 Discussion
-
- 12:30 Lunch
-

-
- 13:15/ **GIST – “resistant”**
14:45 *Chairs: Javier Martin-Broto, Palma de Mallorca, Spain and To be announced*
- 13:15 SDH Mutant GIST
Lee Helman, Bethesda, MD, US
- 13:30 The spectrum of secondary resistance
Jonathan A. Fletcher, Boston, MA, US
- 13:45 Tracking tumour resistance: What's the future?
George S. Demetri, Boston, MA, US
- 14:00 Personalising surgery in advanced disease
Peter Hohenberger, Mannheim, Germany
- 14:15 Recent drugs: Regorafenib
Peter Reichardt, Berlin, Germany
- 14:30 Discussion
-
- 14:45/ **Desmoid tumours**
16:00 *Chairs: Ioannis Boukovinas, Thessaloniki, Greece and Franco Gherlinzoni, Udine, Italy*
- 14:45 Can molecular biology help?
Alexander Lazar, Houston, TX, US
- 15:00 Beyond abdominal, extra-abdominal, intra-abdominal desmoids
Scott M. Schuetze, Ann Arbor, MI, US
- 15:15 The present and the future of medical therapy
William D. Tap, New York, NY, US
- 15:30 Personalising treatment strategy throughout patient history
Palma Dileo, London, UK
- 15:45 Discussion
-
- 16:00 Coffee break
-
- 16:20/ **STS - Localised disease**
17:35 *Chairs: Alexander Fedenko, Moscow, Russian Federation and Kirsten Sundby Hall, Oslo, Norway*
- 16:20 Personalising surgical margins in limb STS
Chandrajit Raut, Boston, MA, US
- 16:35 Personalising surgical margins in retroperitoneal sarcomas
Alessandro Gronchi, Milan, Italy
- 16:50 Personalising indications to radiation therapy
Rick L. Haas, Amsterdam, Netherlands
- 17:05 Personalising adjuvant chemotherapy choices
Axel Le Cesne, Villejuif, France
- 17:20 Discussion
-

-
- 17:35/ **Uterine sarcoma**
18:35 *Chairs: Xavier Garcia del Muro, Barcelona, Spain and Isabelle Ray-Coquard, Lyon, France*
- 17:35 The strange pathology of uterine sarcoma
A. Paolo Dei Tos, Treviso, Italy
- 17:50 Open issues in low-grade uterine mesenchymal tumours
Paolo G. Casali, Milan, Italy
- 18:05 Open issues in high-grade uterine mesenchymal tumours
Martee Hensley, New York, NY, US
- 18:20 Discussion
-
- 18:35 Welcome reception
-

Wednesday, 19 February 2014

- 08:15/ **How to study sarcomas**
09:15 *Chairs: Massimo Aglietta, Turin, Italy and Thor A. Alvegaard, Lund, Sweden*
- 08:15 Clinical end-points
Saskia Litière, Brussels, Belgium
- 08:30 Study designs
Valter Torri, Milan, Italy
- 08:45 Methodological paradigms
Paolo Bruzzi, Genoa, Italy
- 09:00 Discussion
-
- 09:15/ **Molecularly-targeted STS... (Part I)**
10:15 *Chairs: Piero Picci, Bologna, Italy and Patrick Schöffski, Leuven, Belgium*
- 09:15 Molecular targets in sarcomas
Poul H. Sorensen, Vancouver, BC, Canada
- 09:30 Dermatofibrosarcoma
Piotr Rutkowski, Warsaw, Poland
- 09:45 Giant-cell mesenchymal tumours
David Thomas, Melbourne, Australia
- 10:00 PEComa
Andrew Wagner, Boston, MA, US
-
- 10:15 Coffee break
-

10:45/ **Molecularly-targeted STS... (Part II)**

11:45 *Chairs: Piero Picci, Bologna, Italy and
Patrick Schöffski, Leuven, Belgium*

10:45 Solitary fibrous tumours
Silvia Stacchiotti, Milan, Italy

11:00 Recent drugs: Trabectedin
Maurizio D'Incalci, Milan, Italy

11:15 Recent drugs: Pazopanib
Ian Judson, London, UK

11:30 Discussion

11:45/ **...and good old STS as a whole**

12:45 *Chairs: Stefano Ferrari, Bologna, Italy and
Rolf Issels, Munich, Germany*

11:45 Personalising good old surgery of lung metastases
Ugo Pastorino, Milan, Italy

12:00 Personalising good old chemotherapy
Sheyras Patel, Houston, TX, US

12:15 Next generation sequencing: A zoom on sarcomas genomics
Roberta Maestro, Aviano, Italy

12:30 Discussion

12:45 Lunch

13:45/ **Neglected sarcomas**

15:30 *Chairs: Bass Hassan, Oxford, UK and
Vittorio Quagliuolo, Milan, Italy*

13:45 Why are translocation-related sarcomas not necessarily targetable?
Stephen Lessnick, Salt Lake City, UT, US

14:00 The biology of malignant peripheral nerve sheath tumours
Enrique De Alava, Sevilla, Spain

14:15 The spectrum of myoepithelial tumours
Agnès Neuville, Bordeaux, France

14:30 The spectrum of haemangioendotheliomas
Judith Bovée, Leiden, Netherlands

14:45 The spectrum of pleomorphic STS
Jean-Michel Coindre, Villejuif, France

15:00 Desmoplastic small round cell tumour: The need for a global effort
Winette van der Graaf, Nijmegen, Netherlands

15:15 Discussion

15:30 Coffee break

16:00/ Take home messages

17:30 *Chairs: Alessandro Comandone, Turin, Italy and Mikael Eriksson, Lund, Sweden*

16:00 Personalising local treatment of STS, in brief
Raphael Pollock, Columbus, OH, US

16:15 Personalising medical therapy of STS, in brief
Robert S. Benjamin, Houston, TX, US

16:30 What ESMO Guidelines could, and couldn't, acknowledge
Jean-Yves Blay, Lyon, France

16:45 What NCCN Guidelines could, and couldn't, acknowledge
Margareth von Mehren, Philadelphia, PA, US

17:00 Promising targeted drugs in selected STS histologies
Robert Maki, New York, NY, US

17:15 Discussion

17:30/ Closing remarks

17:45 *Chairs: Paolo G. Casali, Milan, Italy and A. Paolo Dei Tos, Treviso, Italy*

17:30 How to translate all this in clinical practice
Jean-Yves Blay, Lyon, France

INVITED SPEAKER DISCLOSURES

Benjamin Robert S.	Johnson & Johnson, Merck and Pfizer
Blay Jean-Yves	Receipt of grants/research supports: Roche, GSK, Novartis. Receipt of honoraria or consultation fees: Pharmamar
Bruzzi Paolo	The author has declared no conflicts of interest
Casali Paolo G.	Receipt of honoraria or consultation fees: Bayer, GSK, Janssen, Merck, Novartis, Pfizer, Pharmamar
Coindre Jean-Michel	The author has declared no conflicts of interest
De Alava Enrique	Receipt of grants/research supports: Pfizer, PharmaMar, Celgene, AstraZeneca. Receipt of honoraria or consultation fees: Glaxo
Debiec-Rychter Maria	The author has declared no conflicts of interest
Dei Tos A. Paolo	Receipt of grants/research supports: Novartis. Participation in a company sponsored speaker's bureau: Novartis, GSK, Pfizer
DeMatteo Ronald P.	Receipt of honoraria or consultation fees: Novartis
Demetri George S.	Consultant, consulting fees: Bayer, Novartis, Pfizer, Sanofi Oncology, Merck, GSK, Ariad
D'Incalci Maurizio	Receipt of grants/research supports and Receipt of honoraria or consultation fees: PharmaMar
Fletcher Jonathan A.	The author has declared no conflicts of interest
Gronchi Alessandro	Receipt of grants/research supports: PharmaMar. Receipt of honoraria or consultation fees: Novartis and Pfizer. Participation in a company sponsored speaker's bureau: Novartis
Haas Rick L.	The author has declared no conflicts of interest
Helman Lee	The author has declared no conflicts of interest
Hensley Martee	Spouse: Sanofi employee
Hohenberger Peter	Receipt of grants/research supports: Novartis. Receipt of honoraria or consultation fees: Novartis, Pfizer, Bayer
Joensuu Heikki	The author has declared no conflicts of interest
Judson Ian	Receipt of grants/research supports: AstraZeneca, GSK, PharmaMar, Eisai, Novartis. Receipt of honoraria or consultation fees: GSK, Novartis. Participation in a company sponsored speaker's bureau: GSK
Lazar Alexander	The author has declared no conflicts of interest
Le Cesne Axel	Receipt of honoraria or consultation fees: Pfizer, PharmaMar, GSK, Novartis
Lessnick Stephen	Other support: Salarius Pharmaceuticals

Maestro Roberta	The author has declared no conflicts of interest
Maki Robert	No disclosure at time of going to press
Montemurro Michael	No disclosure at time of going to press
Neuville Agnes	The author has declared no conflicts of interest
Pastorino Ugo	The author has declared no conflicts of interest
Patel Sheyras	Receipt of grants/research supports: J&J, Pharmamar, Infinity, Eisai, Morphotek. Receipt of honoraria or consultation fees: Novartis, GSK, J&J
Pierotti Marco A.	The author has declared no conflicts of interest
Pollock Raphael	The author has declared no conflicts of interest
Raut Chandrajit	The author has declared no conflicts of interest
Reichardt Peter	Receipt of grants/research supports: Novartis. Receipt of honoraria or consultation fees and Participation in a company sponsored speaker's bureau: Novartis, Pfizer, Bayer, MSD, PharmaMar, Amgen, GSK, Eisai
Rutkowski Piotr	Receipt of honoraria or consultation fees: Novartis, GSK, Bayer, MSD, Pfizer, BMS. Participation in a company sponsored speaker's bureau: Novartis. GSK, Roche
Schuetze Scott M.	Receipt of grants/research supports: SARC, Novartis. Receipt of honoraria or consultation fees: Amgen. Participation in a company sponsored speaker's bureau: Novartis
Sorensen Poul H.	No disclosure at time of going to press
Stacchiotti Silvia	Receipt of grants/research supports: Pfizer; GSK; Bayer; Pharmamar.
Tap William D.	Receipt of honoraria or consultation fees: Plexxikon, Novartis, EMD Serono. Other support: IDMC Chair, Morphotek
Thomas David	The author has declared no conflicts of interest
Trent Jonathan C.	The author has declared no conflicts of interest
Van der Graaf Winette	No disclosure at time of going to press
Von Mehren Margareth	The author has declared no conflicts of interest
Wagner Andrew	Receipt of honoraria or consultation fees: Novartis
Wardelmann Eva	Receipt of grants/research supports: Novartis. Receipt of honoraria or consultation fees: Novartis, Pfizer
Wilson Roger	Receipt of honoraria or consultation fees: Novartis, GSK, Amgen, AstraZeneca